Precipio, Inc. (PRPO) stock
Close on Nov 12, 2026Market cap $41.62MP/E –Yield –
Precipio, Inc. grew revenue 21.8% to $27.76M over the twelve months to Sep 30, 2026. Free cash flow was $1.39M, up 135.5% from a year earlier. At the latest close the market valued the company at $41.62M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $41.62M
- P/E ratio
- –
- Price to sales
- 1.50
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 3.33%
Fundamentals
- Revenue
- $27.76M
- Net income
- -$1.14M
- EPS, diluted
- -$0.63
- Free cash flow
- $1.39M
- Diluted shares
- 2M
Trading
- Next earnings
- Feb 26, 2027 (estimated, during market hours)
- Previous close
- $24.80
- Open
- $24.57
- Day's range
- $22.15 – $24.80
- Volume
- 22,939
- Average volume (20 days)
- 30,592
- Beta (5 years)
- 0.78
- 52-week range
- $17.79 – $33.63
- RSI (14 days)
- 57.4
- Volatility (1 year)
- 65.1%
- Relative volume
- 0.23×
- WACC
- 8.8%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | PRPO | S&P 500 | Difference | PRPO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +2.9% | -2.7% | +5.6 pts | ||
| 3 months | +3.1% | -1.7% | +4.9 pts | ||
| Year to date | +1.2% | +11.9% | −10.7 pts | ||
| 1 year | +16.3% | +12.0% | +4.3 pts | ||
| 3 years | +184.0% | +78.2% | +105.8 pts | +41.6% | +21.2% |
| 5 years | -49.9% | +73.2% | −123.1 pts | -12.9% | +11.6% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Precipio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Update
- Results
About Precipio
Laboratory Analytical Instruments
Precipio is a healthcare biotechnology company that focuses on cancer diagnostics, particularly hematologic malignancies. The company operates through two complementary divisions: pathology services and products. The pathology services division delivers advanced oncology testing, such as molecular diagnostics and cytogenetics, to physicians, clinics, hospitals, and external laboratories. In parallel, the products division develops and commercializes proprietary diagnostic assays and culture media, including its HemeScreen test panels and IV-Cell media, for use by clinical laboratory customers.
Company profile, executives and historyPrecipio stock: common questions
What is Precipio's stock price?
PRPO closed at $23.25 on Nov 12, 2026, down 6.25% on the day. Over the past 52 weeks it traded between $17.79 and $33.63.
What is Precipio's market cap?
Precipio was worth $41.62M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is PRPO's P/E ratio?
Precipio lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.63), so it has no meaningful P/E ratio.
How much revenue does Precipio make?
Precipio reported revenue of $27.76M for the twelve months to Sep 30, 2026, up 21.8% from a year earlier.
Does Precipio pay a dividend?
No. Precipio has not paid a cash dividend over the last twelve months.
When does Precipio report earnings next?
Precipio is expected to report Q4 FY2026 results on Feb 26, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has PRPO stock performed over the past year?
Including dividends, PRPO returned +16.3% over the past year, against +12.0% for the S&P 500.
How many PRPO shares are sold short?
0M shares were sold short at the latest FINRA report, 3.85% of the float, or 1.5 days of average trading volume.
Who are Precipio's competitors?
Companies most similar to Precipio by business, industry and size include BNGO, IDXG, RPID, HBIO, QTRX.
See a number that looks wrong?